LUMA Vision
Developing Verafeye, a technology to enhance the treatment of Atrial Fibrillation and cardiac arrhythmias. .
- B2B
- manufacturing
- health
- biotechnology
- medical devices
- health platform
- artificial intelligence
- hardware
- big data
- deep tech
- biotechnology
- horizon europe
- dt and ls
- spinout
- core ai
- ai applications
- eit ecosystem
- ai agents
- cardiology and cardiovascular
- eit health
- health it
- physician support tools
- eicfund
- medical imaging
- clinical decision support
- precision medicine
- headstart (eit health)
- medical data
- ai for medical imaging
- medical data systems
- headstart 2018 (eit health)
- ivd
| EUR | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
More about LUMA Vision
EditDeveloper of connected intra-vascular medical devices designed to help facilitate the treatment of cardiac arrhythmia. The company utilizes artificial intelligence (AI) and real-time tissue analysis through advanced four-dimensional imaging and improves the way EP and structural heart interventions are treated, enabling doctors to perform cardiac treatments that improve outcomes for patients, increase procedural safety and reduce the cost to the healthcare system.
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.